Peptic ulcer of the stomach and duodenum; prevention of ulcer recurrence. Inflammation of the esophagus in the course of gastroesophageal reflux. The Zollinger-Ellison team. Prevention of duodenal ulcer caused by taking non-steroidal anti-inflammatory drugs. Prevention of Mendelson syndrome (before general anesthesia, in patients who are at risk of aspiration of acid). Prevention of bleeding from stress ulcer.
Composition:
1 tabl powl. contains 150 mg of Ranitidine as hydrochloride.
Action:
Competitive antagonist of the histamine H receptor2 in the stomach mucosa. It reduces both basal and auxiliary secretion of hydrochloric acid and reduces the secretion of pepsin in gastric juice. After oral administration, it is rapidly absorbed from the gastrointestinal tract. The maximum concentration in the blood reaches after about 2-3 hours. Food and antacids, taken together with Ranitidine, slightly reduce the absorption of the drug. T0,5 is about 2-3 hours. Ranitidine is excreted in the urine (60-70%) and faeces (26%), mainly in unchanged form and to a small extent in the form of metabolites.
Contraindications:
Hypersensitivity to ranitidine or other ingredients of the preparation.
Precautions:
Caution should be used in patients with acute renal failure, when concomitant use of non-steroidal anti-inflammatory drugs and ranitidine, especially in the elderly and patients with a history of peptic ulcer. Avoid using this medicine in patients with a history of acute porphyria. Smoking reduces the effectiveness of ranitidine treatment.
Pregnancy and lactation:
Ranitidine crosses the placenta barrier, but the healing doses given to patients during labor and before the caesarean section did not have a detrimental effect on the delivery or later on the development of the infant. It penetrates into breast milk. Ranitidine can be given during pregnancy and breastfeeding only if clearly necessary.
Side effects:
Very rare: usually transient decreases in the number of leukocytes and platelets, cases of agranulocytosis or aplastic anemia, sometimes with partial or total bone marrow suppression, anaphylactic shock, transient convulsions, depression and hallucinations, headache and dizziness, transient involuntary movements, transient blurred vision, relief of cardiac function and atrioventricular block, vasculitis, acute pancreatitis, diarrhea, usually transient hepatitis (cellular, tubular or mixed) with jaundice or without jaundice, erythema multiforme, alopecia, joint and muscular pain, acute interstitial nephritis , transient impotence, enlargement of the breast gland in men. Rarely: hypersensitivity reactions (urticaria, angioneurotic edema, fever, bronchospasm, hypotension, chest pain), transient liver enzymes, skin rashes.
Dosage:
Active gastric and duodenal ulcer: 150 mg 2 times a day, in the morning and at bedtime or 300 mg once a day before bedtime (treatment lasts 4-8 weeks). Prevention of peptic ulcer recurrence: 150 mg once daily at bedtime. Inflammation of the esophagus in the course of gastro-oesophageal reflux: 150 mg 2 times a day for 2 weeks. If necessary, treatment can be repeated. Zollinger-Ellison syndrome: 150 mg 3 times a day. If necessary, the dose can be increased to 6 g a day. Prevention of duodenal ulcer associated with the use of NSAIDs: 150 mg 2 times a day during the use of anti-inflammatory drugs. Prevention of Mendelson syndrome: 150 mg in the evening on the day before the procedure and then 150 mg for 2 hours before anesthesia. Prevention of bleeding from stress ulcer: 150 mg twice daily. Children and adolescents: 2-4 mg / kg / day twice daily, up to a maximum of 300 mg daily. For patients with creatinine clearance below 50 ml / min, use 150 mg daily (in the evening). If necessary, the dose can be increased to 150 mg 2 times a day.In patients with chronic dialysis, ranitidine 150 mg should be administered immediately after dialysis. Ranitidine can be taken at meal time as well as on an empty stomach.
(C)
